HIC
TEVA icon

Hartline Investment Corp’s Teva Pharmaceuticals TEVA Stock Holding History

Hartline Investment Corp’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-32,097
Closed -$503K – 116
2019
Q1 		$503K Buy
32,097
+125
+0.4% +$2.2K 0.13% 86
2018
Q4 		$493K Sell
31,972
-150
-0.5% -$3.08K 0.15% 83
2018
Q3 		$692K Sell
32,122
-125
-0.4% -$2.9K 0.16% 81
2018
Q2 		$784K Sell
32,247
-1,785
-5% -$36.4K 0.21% 69
2018
Q1 		$582K Sell
34,032
-470
-1% -$9.18K 0.16% 80
2017
Q4 		$654K Sell
34,502
-3,001
-8% -$45.1K 0.18% 80
2017
Q3 		$660K Hold
37,503
– – 0.2% 79
2017
Q2 		$1.25M Buy
37,503
+200
+0.5% +$6.19K 0.4% 58
2017
Q1 		$1.2M Sell
37,303
-345
-0.9% -$11.8K 0.39% 61
2016
Q4 		$1.36M Sell
37,648
-1,125
-3% -$44.9K 0.48% 54
2016
Q3 		$1.78M Sell
38,773
-39
-0.1% -$2.04K 0.64% 41
2016
Q2 		$1.95M Sell
38,812
-20
-0.1% -$1.06K 0.7% 36
2016
Q1 		$2.08M Hold
38,832
– – 0.76% 34
2015
Q4 		$2.55M Buy
38,832
+6,169
+19% +$381K 0.95% 29
2015
Q3 		$1.84M Sell
32,663
-7,694
-19% -$499K 0.67% 35
2015
Q2 		$2.38M Sell
40,357
-266
-0.7% -$16.4K 0.79% 41
2015
Q1 		$2.53M Sell
40,623
-89
-0.2% -$5.17K 0.83% 38
2014
Q4 		$2.34M Hold
40,712
– – 0.78% 39
2014
Q3 		$2.19M Sell
40,712
-55
-0.1% -$2.91K 0.79% 41
2014
Q2 		$2.14M Sell
40,767
-30
-0.1% -$1.53K 0.77% 43
2014
Q1 		$2.16M Buy
40,797
+120
+0.3% +$5.55K 0.74% 48
2013
Q4 		$1.63M Hold
40,677
– – 0.57% 54
2013
Q3 		$1.54M Hold
40,677
– – 0.6% 53
2013
Q2 		$1.59M Buy
+40,677
New +$1.58M 0.64% 51

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Berkshire Hathaway
Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Hartline Investment Corp's TEVA Position: Q2 2019 in Review

Hartline Investment Corp sold out of Teva Pharmaceuticals (TEVA) in Q2 2019, closing a stake of 32,097 shares — an estimated $503K sold.

Hartline Investment Corp first reported a position in TEVA in Q2 2013 and held it in 24 quarters. The position peaked at $2.55M in Q4 2015. 452 funds tracked by Wall St. Rank hold TEVA as of Q2 2019.

  • Hartline Investment Corp reported no remaining Teva Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • Hartline Investment Corp sold 32,097 Teva Pharmaceuticals shares in Q2 2019, an estimated $503K.
  • Hartline Investment Corp first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 24 quarters.
  • Hartline Investment Corp's Teva Pharmaceuticals position peaked at $2.55M in Q4 2015.
  • 452 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2019.

Based on Hartline Investment Corp's 13F filing for Q2 2019, filed 8 Aug 2019.